Pathalys Pharma Stock

Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.

Sign up today and learn more about Pathalys Pharma Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Pathalys Pharma Stock

Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease. Pathalys' initial focus will be on improving treatment for secondary hyperparathyroidism, which is an unmet need (SHPT). SHPT is a condition in which a disease outside of the parathyroid glands causes all of the parathyroid glands to swell and become hyperactive, producing an excessive amount of parathyroid hormone (PTH).

Funding History

June 2021$11.0M
January 2023$150M

Management

Co-Founder

Mahesh Krishnan

Co-Founder

Jay P. Shepard

Board Member

Neal Fowler

Co-Founder

Takeshi Takahashi

Co-Founder

Ashwin Ram

Co-Founder and Executive Chairman

BT Slingsby

CEO

Neal Fowler

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo